Innate Pharma

Innate drops monotherapy plans for lacutamab in type of lymphoma

Two months after the FDA lifted a hold on Innate's lymphoma drug, the biotech drops plans for the antibody as a monotherapy for a form of that cancer.

James Waldron Mar 21, 2024 8:27am

Scorpion taps new CEO, CMO—Chutes & Ladders

Jan 5, 2024 9:30am

Innate secures speedy resolution of FDA hold on lymphoma trials

Jan 4, 2024 9:50am

Innate lymphoma trials put on partial hold after patient dies

Oct 5, 2023 6:20am

Madrigal snags Sanofi exec as CEO—Chutes & Ladders

Sep 15, 2023 9:30am

Takeda taps Innate to develop celiac antibody-drug conjugates

Apr 3, 2023 5:08am